Laurion Capital Management LP purchased a new position in Radius Health Inc (NASDAQ:RDUS) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 146,643 shares of the biopharmaceutical company’s stock, valued at approximately $2,610,000. Laurion Capital Management LP owned about 0.32% of Radius Health at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Raymond James & Associates raised its holdings in shares of Radius Health by 15.0% in the second quarter. Raymond James & Associates now owns 18,766 shares of the biopharmaceutical company’s stock worth $553,000 after buying an additional 2,449 shares during the last quarter. State of Wisconsin Investment Board increased its stake in shares of Radius Health by 7.0% in the second quarter. State of Wisconsin Investment Board now owns 41,200 shares of the biopharmaceutical company’s stock worth $1,214,000 after acquiring an additional 2,700 shares during the period. BTG Pactual Global Asset Management Ltd increased its stake in shares of Radius Health by 30.5% in the second quarter. BTG Pactual Global Asset Management Ltd now owns 22,918 shares of the biopharmaceutical company’s stock worth $675,000 after acquiring an additional 5,356 shares during the period. NumerixS Investment Technologies Inc acquired a new stake in shares of Radius Health in the second quarter worth $162,000. Finally, Alps Advisors Inc. increased its stake in shares of Radius Health by 10.3% in the second quarter. Alps Advisors Inc. now owns 65,973 shares of the biopharmaceutical company’s stock worth $1,944,000 after acquiring an additional 6,165 shares during the period.
A number of research firms have recently weighed in on RDUS. Cowen reiterated a “hold” rating on shares of Radius Health in a research note on Thursday, October 18th. Zacks Investment Research lowered shares of Radius Health from a “hold” rating to a “sell” rating in a research note on Tuesday, October 9th. BidaskClub upgraded shares of Radius Health from a “strong sell” rating to a “sell” rating in a research note on Tuesday, November 27th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Radius Health from $59.00 to $52.00 and set an “overweight” rating on the stock in a research note on Friday, November 2nd. Two research analysts have rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $44.38.
NASDAQ:RDUS opened at $15.84 on Friday. Radius Health Inc has a 1-year low of $14.52 and a 1-year high of $41.16. The company has a quick ratio of 5.39, a current ratio of 5.50 and a debt-to-equity ratio of 1.85.
Radius Health (NASDAQ:RDUS) last released its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.26) by $0.17. The firm had revenue of $27.70 million for the quarter, compared to analyst estimates of $26.00 million. Radius Health had a negative net margin of 346.67% and a negative return on equity of 140.79%. The business’s quarterly revenue was up 105.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.31) earnings per share. As a group, equities analysts predict that Radius Health Inc will post -5.17 earnings per share for the current year.
About Radius Health
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide that is in Phase III clinical trial to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator that is in Phase I clinical trial to treat breast cancer.
See Also: Derivative
Want to see what other hedge funds are holding RDUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Radius Health Inc (NASDAQ:RDUS).
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.